SNCA and synucleinopathy: These vaccine candidates have demonstrated the potential to elicit an immune‐specific response against alpha‐synuclein fibrils derived from a mouse model of synucleinopathy, supporting our novel approach for vaccine development targeting PD and other synucleinophaties (Figure 5).